These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

119 related articles for article (PubMed ID: 17382964)

  • 1. Immunosuppression: promises and failures.
    Oger J
    J Neurol Sci; 2007 Aug; 259(1-2):74-8. PubMed ID: 17382964
    [TBL] [Abstract][Full Text] [Related]  

  • 2. [Immunosuppressive medication in multiple sclerosis].
    García Merino JA
    Rev Neurol; 2002 Dec 16-31; 35(12):1154-8. PubMed ID: 12497298
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Immunosuppressive treatment in multiple sclerosis].
    Vermeulen M; Zegerius L; van Crevel H
    Ned Tijdschr Geneeskd; 1987 Jan; 131(3):93-6. PubMed ID: 3821989
    [No Abstract]   [Full Text] [Related]  

  • 4. [Immunosuppressants and multiple sclerosis].
    Ruiz-Peña JL; Izquierdo-Ayuso G
    Rev Neurol; 2002 Aug 16-31; 35(4):373-80. PubMed ID: 12235571
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The therapy of multiple sclerosis with immune-modulating or immunosuppressive drug. A critical evaluation based upon evidence based parameters and published systematic reviews.
    Clerico M; Rivoiro C; Contessa G; Viglietti D; Durelli L
    Clin Neurol Neurosurg; 2008 Nov; 110(9):878-85. PubMed ID: 18164542
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of multiple sclerosis using immunosuppression. Critical discussion of results].
    Hommes OR
    Ned Tijdschr Geneeskd; 1976 Mar; 120(10):424-30. PubMed ID: 765862
    [No Abstract]   [Full Text] [Related]  

  • 7. Combination therapy for the treatment of multiple sclerosis: challenges and opportunities.
    Stuart WH
    Curr Med Res Opin; 2007 Jun; 23(6):1199-208. PubMed ID: 17559719
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Critical opinions on the treatment of multiple sclerosis with immunosuppressive agents].
    Skłodowski P
    Neurol Neurochir Pol; 1993; 27(6):877-83. PubMed ID: 8164783
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Intensive immunosuppression in multiple sclerosis.
    Zaffaroni M; Ghezzi A; Comi G
    Neurol Sci; 2006 Mar; 27 Suppl 1():S13-7. PubMed ID: 16708175
    [TBL] [Abstract][Full Text] [Related]  

  • 10. [Immunosuppressive therapy of multiple sclerosis using cyclophosphamide with few side effects].
    Kornhuber HH; Mauch E
    Dtsch Med Wochenschr; 1986 Nov; 111(46):1778. PubMed ID: 3780443
    [No Abstract]   [Full Text] [Related]  

  • 11. Long-term experience with induction treatment regimens in multiple sclerosis.
    Le Page E; Edan G
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S46-9. PubMed ID: 19200867
    [TBL] [Abstract][Full Text] [Related]  

  • 12. [Mitoxantrone for the treatment of patients with multiple sclerosis].
    Komori M; Kondo T; Tanaka M
    Brain Nerve; 2009 May; 61(5):575-80. PubMed ID: 19514518
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The limitations of immunosuppressant therapy in Multiple Sclerosis.
    Sedal L
    J Clin Neurosci; 2000 Nov; 7(6):563-4; discussion 564-5. PubMed ID: 11029245
    [No Abstract]   [Full Text] [Related]  

  • 14. Immunosuppression for multiple sclerosis.
    N Engl J Med; 1983 Jul; 309(4):239-41. PubMed ID: 6866042
    [No Abstract]   [Full Text] [Related]  

  • 15. Immunosuppressive therapy in multiple sclerosis.
    Edan G
    Neurol Sci; 2005 May; 26 Suppl 1():S18. PubMed ID: 15883680
    [No Abstract]   [Full Text] [Related]  

  • 16. Moving on to second-line therapies in pediatric MS: Immunosuppression with cyclophosphamide.
    Yeh EA; Weinstock-Guttman B
    Neurology; 2009 Jun; 72(24):2064-5. PubMed ID: 19439721
    [No Abstract]   [Full Text] [Related]  

  • 17. Multiple sclerosis. Part 2: ophthalmic issues in MS therapy.
    Pula JH; Javed A
    Curr Opin Ophthalmol; 2009 Nov; 20(6):476-81. PubMed ID: 19816177
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetics and pharmacodynamics of the interferon-betas, glatiramer acetate, and mitoxantrone in multiple sclerosis.
    Neuhaus O; Kieseier BC; Hartung HP
    J Neurol Sci; 2007 Aug; 259(1-2):27-37. PubMed ID: 17391705
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Autologous stem-cell transplantation in malignant multiple sclerosis: a case with a favorable long-term outcome.
    Kimiskidis V; Sakellari I; Tsimourtou V; Kapina V; Papagiannopoulos S; Kazis D; Vlaikidis N; Anagnostopoulos A; Fassas A
    Mult Scler; 2008 Mar; 14(2):278-83. PubMed ID: 17942513
    [TBL] [Abstract][Full Text] [Related]  

  • 20. The future of multiple sclerosis treatment.
    Cohen JA
    J Neurol Sci; 2009 Feb; 277 Suppl 1():S55-61. PubMed ID: 19200869
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 6.